|Bid||3.7500 x 1800|
|Ask||4.1000 x 900|
|Day's Range||3.6500 - 4.0000|
|52 Week Range||1.6000 - 5.2500|
|Beta (5Y Monthly)||N/A|
|PE Ratio (TTM)||N/A|
|Earnings Date||Aug 10, 2020 - Aug 14, 2020|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||9.60|
Aptinyx Inc. (APTX) has been upgraded to a Zacks Rank 1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
One thing we could say about the analysts on Aptinyx Inc. (NASDAQ:APTX) - they aren't optimistic, having just made a...
Aptinyx Inc. (NASDAQ:APTX) missed earnings with its latest first-quarter results, disappointing overly-optimistic...
Aptinyx Inc. (APTX) delivered earnings and revenue surprises of -3.03% and -9.61%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
Aptinyx Inc. (APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today reported financial results for the first quarter of 2020 and highlighted recent progress across the company’s clinical programs and pipeline of novel NMDA receptor modulators. “In the midst of the COVID-19 global pandemic, the safety of our employees, colleagues, and patients participating in our clinical studies remains our top priority,” said Norbert Riedel, Ph.D., president and chief executive officer of Aptinyx. Achieved over 90% of target patient enrollment to date in Phase 2 exploratory study of NYX-783 in post-traumatic stress disorder (PTSD).
Aptinyx Inc (APTX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Wall Street is experiencing some major déjà vu. The tensions between the U.S. and China flared after President Trump threatened to impose new import tariffs. The difference this time? These tariffs would serve as a punishment for China’s role in the COVID-19 pandemic. In response, stocks posted sharp declines, a rough start to the month of May.The new week of trading could see more of the same. U.S. stock pointed to losses in Monday's trading session as statements made by U.S. Secretary of State Mike Pompeo the day before failed to alleviate trade war fears. Going off of the administration’s earlier statements, Pompeo supported the President’s claim that the virus originated in a Wuhan, China laboratory, adding that the country also stocked up on medical supplies while covering up the extent of COVID-19's spread.The possibility that a trade war could be reignited has spooked market watchers, but for those looking at the glass half full, there’s a silver lining. Compelling names have seen their share prices driven lower, presenting investors with more attractive entry points. Seasoned Street veterans argue this is particularly true of the biotech space, with this area of the market holding up better than others.Bearing this in mind, we set out to find exciting yet affordable opportunities within the biotech industry. Using TipRanks’ database, we found three stocks trading for under $10 per share that fit the bill, with each offering up “Strong Buy” consensus ratings from the analyst community and plenty of upside potential. Here’s the full scoop.Aptinyx (APTX)Using a differentiated approach that involves modulating the N-methyl-D-aspartate (NMDA) receptor via a unique mechanism rather than switching it on or off, Aptinyx develops cutting-edge therapies for brain and nervous system disorders. Deemed “the comeback kid”, at $2.72 per share, now could be the time to pull the trigger before APTX takes off on an upward trajectory.This is the opinion of H.C. Wainwright's Raghuram Selvaraju. The five-star analyst doesn’t dispute that shares have been put through the ringer as of late, but he believes Wall Street has reacted unfairly to non-statistically significant Phase 2 trial results for its lead candidate, NYX-2925, in diabetic neuropathic pain (DPN) early last year.In fact, Selvaraju cites several reasons for his continued optimism. During the DPN trial, there was clear evidence of NYX-2925's activity, which was supported by additional proof of efficacy in a separate Phase 2 study in fibromyalgia. Additionally, NYX-2925's modulation of the N-methyl-D-aspartate (NMDA) receptor is a validated target in the central nervous system (CNS) space. It should be noted that multiple post-hoc analyses on the Phase 2 DPN data were conducted. NYX-2925 is also in a confirmatory Phase 2b trial that incorporates the discoveries from the Phase 2 study, and the current trial is evaluating a single dose vs. Placebo, making it more robustly powered than the earlier trial.All of this prompted Selvaraju to comment, “From our vantage point, the lack of value being attributed to Aptinyx's technology platform, lead asset and pipeline provides an intriguing entry point for those investors willing to judge the clinical data on its own merits. We also note the precedent cases of gabapentin and duloxetine, which ultimately achieved market entry in neuropathic pain despite setbacks in DPN trials.”If that wasn’t enough, Selvaraju sees multiple upcoming clinical data catalysts for not only NYX-2925, but also for its NYX-783 asset and NYX-458 candidate. Speaking to the large market opportunity, he added, “We believe that chronic neuropathic pain—whether embodied by DPN or fibromyalgia—constitutes a poorly addressed condition. Furthermore, the recent opioid crisis has made it well-nigh impossible for physicians to rely on opioid drugs for pain management. Accordingly, there is a burgeoning need for non-opioid, non-addictive analgesic agents that work via novel mechanisms. We note that approximately 8 million individuals in the U.S. alone suffer from DPN, while roughly 5 million suffer from fibromyalgia.”It should come as no surprise, then, that Selvaraju decided to join the bulls. To initiate his APTX coverage, he put a Buy rating and $7 price target on the stock, implying 145% upside potential. (To watch Selvaraju’s track record, click here)Turning now to the rest of the Street, other analysts agree with Selvaraju. The stock has received only Buy ratings in the last three months, 4 to be exact, so the consensus rating is a Strong Buy. Given the $10.67 average price target, the upside potential comes in at a whopping 274%. (See Aptinyx stock analysis on TipRanks)Viking Therapeutics (VKTX)Targeting metabolic and endocrine disorders, Viking Therapeutics’ technology could be a game changer, with it boasting lead candidate, VK2809, an orally available, liver selective thyroid hormone receptor β (TRβ) agonist. Given its vast potential in this area of medicine, several members of the Street believe that at $5.45 apiece, it’s undervalued.Digging a bit deeper into VKTX’s technology, TRβ agonists are powerful anti-steatotic drugs (reducers of liver fat) that could be capable of reversing NASH and even fibrosis, based on available clinical data. In addition, TRβs are safe and convenient oral drugs that demonstrate efficacy close to the levels seen in injectables with significantly less clear safety windows.Writing for BTIG, analyst Julian Harrison noted, “Within the TRβ space, we believe VK2809 is positioned to be best-in-class with a favorable mix of potency and tolerability/safety, thanks to calculated prodrug chemistry. Competition from Madrigal’s resmetirom (MGL-3196) has a 2 to 3-year development lead, but in a market of chronic and predominantly asymptomatic disease, safety, tolerability and even ease of administration will matter considerably.”Expounding on the competition with Madrigal, Harrison points out MGL-3196 doesn’t limit systemic exposure, while VKTX’s VK2809 remains in prodrug form outside the liver. This means that VK2809 can generate truly selective activation in the liver, making the issue of targeting bias a nonissue.Even though COVID-19 has caused industry-wide delays, twelve-month biopsy data from the Phase 2b trial of VK2809 in patients with biopsy-confirmed NASH shouldn’t face much of a disruption.“Overall, we view VK2809’s strong clinical data and the enterprise value of only $140 million as a chance for investors to invest in an undervalued asset ahead of de-risked POC readouts,” Harrison concluded.Taking all of this into consideration, Harrison kicked off his VKTX coverage by publishing a Buy rating. The analyst also set a $9 price target, which indicates shares could climb 65% higher in the next year.Like Harrison, other Wall Street analysts are optimistic about this biotech’s long-term growth prospects. With 8 Buys assigned in the last three months compared to no Holds or Sells, the message is clear: VKTX is a Strong Buy. Should the $14.86 average price target be met, a twelve-month gain of 153% could be in the cards. (See Viking stock analysis on TipRanks)Mersana Therapeutics (MRSN)Last but not least we have Mersana, a biotech company that develops antibody-drug conjugates (ADCs) for oncology, with its focus on drug payloads designed to deliver more chemotherapy to the tumors and less to the surrounding tissue, particularly the bone marrow. Ahead of several upcoming data readouts, some analysts believe that its $8.23 per share price tag presents investors with a unique buying opportunity.Part of the excitement surrounding MRSN is related to its lead program, XMT-1536. The ADC for later-line ovarian cancer (OC) and non-small-cell lung carcinoma (NSCLC) was designed using two innovative technologies that enable it to spur controlled bystander killing, with it specifically targeting NaPi2b, a clinically validated target over-expressed on several important tumor types. It should be noted that XMT-1536 is already progressing through dose-ranging studies and data has demonstrated it is active in platinum-resistant OC and NSCLC adenocarcinomas.Representing BTIG, five-star analyst Thomas Shrader argues that key data sets, which are scheduled for release in the second half of 2020, could de-risk XMT-1536 in both OC and NSCLC, as well as fuel even more upside by “further validating the Mersana ADC platform and its application in the earlier-stage pipeline.” He added, “The ~33% ORR seen in very late-line NaPi2b-high OC patients (at dose ≥ 30 mg/m2) seems likely to be good enough for accelerated approval and should increase in earlier line patients.”According to Shrader, the potential of ADCs can be taken one step further. “We believe the future of ADCs may be to replace the chemo component in chemo + IO combinations. In this approach, Mersana’s safety profile seems well placed, as their drugs to date seem particularly gentle on the patient’s bone marrow while clearly showing tumor killing (and corresponding tumor antigen release). Similarly, the newest focus at Mersana, termed iADCs, should drive increased anti-tumor innate immune responses – an area widely considered to be the next leg of IO,” he explained.When it comes to the balance sheet, MRSN is standing on solid ground. As of Q4 2019, the company had $100 million in cash and cash equivalents, and last month, it exercised its ATM to raise an additional $65 million. This should be enough to support Phase 1 clinical studies of XMT-1536 and Phase 1 dose-expansion studies for its XMT-1592 therapy.Based on everything MRSN has going for it, it’s no wonder Shrader decided to initiate coverage. Along with a Buy recommendation, he set the price target at $14, suggesting 70% upside potential. (To watch Shrader’s track record, click here)All in all, other Wall Street pros echo the BTIG analyst’s sentiment. Out of 4 total reviews issued in the last three months, 100% were bullish, making the consensus rating a Strong Buy. The $13 average price target is less aggressive than Shrader’s, but it still leaves room for shares to gain 53% in the next year. (See Mersana stock analysis on TipRanks)To find good healthcare ideas for stocks trading at attractive valuations, visit TipRanks’ Best Stocks to Buy, a newly launched tool that unites all of TipRanks’ equity insights.
EVANSTON, Ill., April 30, 2020 -- Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain.
The Zacks Analyst Blog Highlights: Airgain, Trilogy Metals, Aptinyx, Veritone and Tufin Software Technologies
Aptinyx Inc. (APTX) has been upgraded to a Zacks Rank 2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Shareholders might have noticed that Aptinyx Inc. (NASDAQ:APTX) filed its annual result this time last week. The early...
Aptinyx Inc. (APTX) delivered earnings and revenue surprises of 30.51% and -2.96%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?
Aptinyx Inc. (APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today reported financial results for the fourth quarter and full year 2019 and provided updates across the company’s pipeline of novel NMDA receptor modulators. Aptinyx has three distinct product candidates in Phase 2 clinical development across three primary therapeutic areas: chronic pain, post-traumatic stress disorder (PTSD), and cognitive impairment. “We made great progress in 2019 across our programs in chronic pain, PTSD, and cognitive impairment, highlighted by the initiation of four Phase 2 studies and positive clinical read-outs on NYX-2925 and NYX-458,” said Norbert Riedel, Ph.D., president and chief executive officer of Aptinyx.
NEW YORK, NY / ACCESSWIRE / March 30, 2020 / Aptinyx, Inc. (NASDAQ:APTX) will be discussing their earnings results in their 2019 Fourth Quarter Earnings call to be held on March 30, 2020 at 5:00 PM Eastern ...
Aptinyx Inc. (APTX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
EVANSTON, Ill., March 18, 2020 -- Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain.
Aptinyx Inc. is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of proprietary synthetic small molecules for the treatment of brain and nervous system disorders. Aptinyx has a platform for discovery of novel compounds that work through a unique mechanism to modulate—rather than block or over-activate—NMDA receptors and enhance synaptic plasticity, the foundation of neural cell communication. The company has three product candidates in clinical development in central nervous system indications, including chronic pain, post-traumatic stress disorder, and cognitive impairment associated with Parkinson’s disease.
EVANSTON, Ill., Jan. 30, 2020 (GLOBE NEWSWIRE) -- Aptinyx Inc. (APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced a publication in Movement Disorders detailing data on its novel NMDAr modulator, NYX-458. The data demonstrate that administration of NYX-458 resulted in a reversal of cognitive deficits in a non-human primate model of Parkinson’s disease. The data were published in the January issue of Movement Disorders, the official journal of the International Parkinson and Movement Disorder Society.
At two of them, the shares were sold in recent secondary offerings. Conventional wisdom says that insiders and 10% owners really only buy shares of a company for one reason — they believe the stock price will rise and they want to profit. The following are a few of significant insider purchases reported last week, all small-cap biotechs.
Aptinyx Inc. (APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced the closing of its public offering of 11,691,666 shares of its common stock, which included the exercise in full of the underwriters’ option to purchase additional shares, at a public offering price of $3.00 per share. All of the shares sold in the offering were sold by Aptinyx. The gross proceeds from the offering, before deducting underwriting discounts and commissions and offering expenses payable by Aptinyx, were approximately $35.1 million.